A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC

Active, not recruitingOBSERVATIONAL

Enrollment

444

Participants

Timeline

Start Date

September 6, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

September 30, 2024

Conditions

Inflammatory Bowel Diseases

Interventions

DRUG

Subcutaneous infliximab CT-P13 Remsima®SC

Patients will be switched from IV infliximab into subcutaneous infliximab Remsima®SC 120 mg.

Trial Locations (1)

Nicolas Mathieu, Grenoble